Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Kura Oncology (KURA – Research Report), boosting the price target to $40.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Joseph Pantginis has given his Buy rating due to a combination of factors including Kura Oncology’s promising clinical advancements and strategic collaborations. The recent positive topline results from the Phase 2 KOMET-001 trial for ziftomenib, a treatment for r/r NPM1-m AML patients, have shown statistically significant success in achieving primary endpoints, along with a favorable safety profile.
Furthermore, the company’s plans to initiate Phase 3 trials for ziftomenib in combination with other therapies for 1L AML patients demonstrate a strong pipeline and potential market expansion. The collaboration with Kyowa Kirin is expected to enhance ziftomenib’s market opportunities, while regulatory pathways have been agreed upon with the FDA, suggesting a potential for accelerated approval. These aspects collectively underpin Pantginis’s confidence in Kura Oncology’s stock performance.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $28.00 price target.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KURA in relation to earlier this year.